Perioperative medicine & outcomes
Ferric carboxymaltose with or without phosphate substitution in iron deficiency or iron deficiency anemia before elective surgery – The DeFICIT trial
Authors' conclusion
Co-administration of oral phosphate supplementation to ferric carboxymaltose cannot prevent hypophosphatemia. However, hypophosphatemia occurs in fewer patients. Phosphate co-administration did not impede the treatment of iron deficiency anemia with ferric carboxymaltose.
Study context
- Population
- Adults with iron deficiency or iron deficiency anaemia (hemoglobin (Hb) 100–130 g/L) scheduled for elective major abdominal or thoracic surgery
- Participants
- 92 adults
- Comparison
- Phosphate vs Placebo
- Phosphaten = 46
- Placebon = 46reference
- Primary endpoint
- Minimum serum phosphate concentration during follow-up visits
Methodological detailssingle-centre, prospective, double-blind, placebo-controlled
- Single-centre
- Prospective
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Minimal phosphate concentration
P = 0.12
Secondary outcomes
Mean perioperative Hb, POD 0, 2 and 4 (key secondary, non-inferiority) · postoperative days 0, 2 and 4 · one-sided · one-sided p-value for non-inferiority
P for non-inferiority = 0.023
%
| Outcome | Phosphate | Placebo | OR (95 % CI) | P value | |
|---|---|---|---|---|---|
| Hypophosphataemia | 70 | 85 | 0.15 (0.02–0.77) | P = 0.014 | |
| 0.050.21520Odds ratio (log scale) |
Rescue medication use, core muscle strength, MOCA test scores
- Did not differ between groups
Original publication
Ferric carboxymaltose with or without phosphate substitution in iron deficiency or iron deficiency anemia before elective surgery – The DeFICIT trial. J Clin Anesth. Published 12 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →